ストックスクリーナーアプリを入手
9.5488
14.31%
1.1788
Fibrogen Inc (FGEN) 最新ニュース
FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances - MSN
FibroGen's Robust Finances and Promising Pipeline Earn Analyst's Buy Rating - AInvest
Fibrogen 2025 Q2 Earnings Record Net Income and Strong Revenue Growth - AInvest
Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD) - The Globe and Mail
FibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... - Yahoo Finance
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FibroGen’s Strategic Moves and Financial Outlook - TipRanks
FibroGen's Strategic Pivot: China Exit and FG-3246's Oncology Promise Fuel Undervalued Biotech Opportunity - AInvest
FibroGen's 2025 Q2: Unraveling Key Contradictions in Roxadustat and FG-3246 Clinical Trial Strategies - AInvest
FibroGen's Q2 2025 Earnings Miss: A Catalyst for Long-Term Value or a Warning Signal? - AInvest
Transcript : FibroGen, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
FibroGen Q2 2025 slides: China sale extends runway amid clinical progress - Investing.com Canada
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
FibroGen: Q2 Earnings Snapshot - San Antonio Express-News
FibroGen's Strategic Turnaround and Financial Resilience: A Path to Value Recovery? - AInvest
FibroGen Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: FibroGen Q2 2025 revenue falls short, stock drops - Investing.com
FibroGen Inc earnings missed by $1.79, revenue fell short of estimates - Investing.com Nigeria
FibroGen's Financial Challenges and Catalyst-Driven Turnaround Potential - AInvest
FibroGen Secures $210M China Deal with AstraZeneca, Advances Cancer Drug Trials - Stock Titan
Fibrogen FGEN 2025Q2 Earnings Preview Upside Potential on Strong Revenue Growth - AInvest
FibroGen shares surge on FDA support for anemia drug in MDS patients - MSN
Is FibroGen Inc. affected by consumer sentimentRocket Return Picks - thegnnews.com
FibroGen Inc expected to post a loss of $2.31 a shareEarnings Preview - TradingView
FibroGen shares rise 11.75% intraday after positive FDA meeting for roxadustat Phase 3 trial. - AInvest
Fibrogen: HC Wainwright Raises PT to $43 from $10, Maintains Buy Rating - AInvest
FibroGen stock surges after FDA feedback on roxadustat for MDS anemia - Investing.com India
FibroGen advances roxadustat for anemia in myelodysplastic syndromes By Investing.com - Investing.com Australia
FibroGen advances roxadustat for anemia in myelodysplastic syndromes - Investing.com
FibroGen Announces Positive Type C Meeting with the FDA for - GlobeNewswire
FDA Green-Lights FibroGen's Novel Oral Treatment for MDS Anemia: 5x Better Than Placebo - Stock Titan
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - MSN
FibroGen to Report Second Quarter 2025 Financial Results - The Manila Times
FibroGen Q2 2025 Earnings Call: Key Financial Results Coming August 11 After Market Close - Stock Titan
FibroGen Inc. Forms Bullish Flag — Upside AheadInvestment Plan With Growth Optimization Finalized - beatles.ru
How does FibroGen Inc. compare to its industry peersHigh-yield growth strategies - Jammu Links News
How volatile is FibroGen Inc. stock compared to the marketCapitalize on market trends with confidence - Jammu Links News
What is the dividend policy of FibroGen Inc. stockInvest confidently with professional guidance - Jammu Links News
Is FibroGen Inc. a good long term investmentRapidly growing investment returns - Jammu Links News
How does FibroGen Inc. generate profit in a changing economyGet exclusive access to premium stock research - Jammu Links News
What institutional investors are buying FibroGen Inc. stockCapitalize on momentum-driven stocks - Jammu Links News
What are analysts’ price targets for FibroGen Inc. in the next 12 monthsLightning-fast capital gains - Jammu Links News
Should I hold or sell FibroGen Inc. stock in 2025Get real-time updates on market trends - Jammu Links News
What are the latest earnings results for FibroGen Inc.Consistent triple-digit returns - Jammu Links News
What is the risk reward ratio of investing in FibroGen Inc. stockRealize exceptional returns through smart trading - Jammu Links News
How strong is FibroGen Inc. company’s balance sheetCapitalize on market shifts with expert advice - Jammu Links News
Press Release: FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
Applying big data sentiment scoring on FibroGen Inc.Quick Gain Stock Watch With Indicators Reviewed - metal.it
Short Interest Drops in FibroGen Inc. After RallyMarket Momentum Signal Generator Shows Trends - beatles.ru
FibroGen Inc. Recovery Potential Based on Technical ToolsTechnical Entry Strategy for Beginners Explained - metal.it
Sector Leaders Rotate Capital Into FibroGen Inc.Trade Timing Strategy With Technical Data Explained - metal.it
0.87%
3.01%
大文字化:
|
ボリューム (24 時間):